Free Trial
NASDAQ:BFRI

Biofrontera (BFRI) Stock Price, News & Analysis

Biofrontera logo
$0.70 -0.23 (-24.39%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.71 +0.01 (+1.84%)
As of 11/13/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Biofrontera Stock (NASDAQ:BFRI)

Advanced

Key Stats

Today's Range
$0.68
▼
$0.96
50-Day Range
$0.70
▼
$1.61
52-Week Range
$0.55
▼
$1.66
Volume
875,774 shs
Average Volume
148,265 shs
Market Capitalization
$10.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Reduce

Company Overview

Biofrontera Inc. is a biopharmaceutical company focused on dermatology and the commercial development of prescription products for treating skin conditions. Its business is primarily centered on the U.S. market.

The company’s main product is Ameluz, a topical gel containing aminolevulinic acid hydrochloride. It is used with Biofrontera’s BF-RhodoLED light device in photodynamic therapy to treat certain actinic keratoses, precancerous lesions that can develop on sun-damaged skin.

Biofrontera’s products combine a topical treatment with a specialized light source, which activates the treatment during a clinical procedure. The company was formerly associated with German pharmaceutical company Biofrontera AG and became an independent U.S. public company in 2023.

AI Generated. May Contain Errors.

Biofrontera Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
12th Percentile Overall Score

BFRI MarketRank™: 
0.592252133945 of 5 stars

Biofrontera scored higher than 12% of companies evaluated by MarketBeat, and ranked 848th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Biofrontera has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Biofrontera has only been the subject of 1 research reports in the past 90 days.

  • Read more about Biofrontera's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Biofrontera is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Biofrontera is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Biofrontera has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.39% of the float of Biofrontera has been sold short.
  • Short Interest Ratio / Days to Cover

    Biofrontera has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Biofrontera has recently increased by 83.84%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Biofrontera does not currently pay a dividend.

  • Dividend Growth

    Biofrontera does not have a long track record of dividend growth.

  • News Sentiment

    Biofrontera has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Biofrontera this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for BFRI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Biofrontera insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    8.10% of the stock of Biofrontera is held by insiders.

  • Percentage Held by Institutions

    10.08% of the stock of Biofrontera is held by institutions.

  • Read more about Biofrontera's insider trading history.
Receive BFRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BFRI Stock News Headlines

Biofrontera (NASDAQ:BFRI) Issues Quarterly Earnings Results
Unbelievable…Congress is About to Do What?
Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washington is set to take place by November 30th. He believes it could create one of the most chaotic environments in America's history. He predicts those who understand what's happening could do very well over the next 12-18 months, while others may face steep losses. Rickards outlines the five steps he recommends.tc pixel
Biofrontera (BFRI) Q3 2026 Earnings Call Transcript
Biofrontera Inc. (BFRI) Stock Falls on Q3 2026 Earnings
See More Headlines

BFRI Stock Analysis - Frequently Asked Questions

Biofrontera's stock was trading at $0.57 at the start of the year. Since then, BFRI shares have increased by 22.8% and is now trading at $0.7001.

Biofrontera Inc. (NASDAQ:BFRI) announced its quarterly earnings data on Friday, November, 13th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.31. The company had revenue of $9.07 million for the quarter, compared to analysts' expectations of $8.50 million. Biofrontera had a negative trailing twelve-month return on equity of 145.81% and a negative net margin of 13.78%.
Read the conference call transcript
.

Biofrontera's stock reverse split on the morning of Wednesday, July 5th 2023.The 1-20 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Biofrontera (BFRI) raised $19 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 3,100,000 shares at $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company served as the underwriters for the IPO.

Biofrontera's top institutional investors include AIGH Capital Management LLC (10.08%).

Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Biofrontera investors own include Lucid Group (LCID), Longeveron (LGVN), Tesla (TSLA), AMC Entertainment (AMC), Ford Motor (F), iSpecimen (ISPC) and Pasithea Therapeutics (KTTA).

Company Calendar

Last Earnings
11/13/2026
Today
11/15/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:BFRI
CIK
1858685
Fax
N/A
Employees
94
Year Founded
2012

Profitability

EPS (Trailing Twelve Months)
($0.45)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$10.54 million
Net Margins
-13.78%
Pretax Margin
-13.72%
Return on Equity
-145.81%
Return on Assets
-31.30%

Debt

Debt-to-Equity Ratio
0.78
Current Ratio
1.18
Quick Ratio
1.08

Sales & Book Value

Annual Sales
$41.71 million
Price / Sales
0.25
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.90 per share
Price / Book
0.78

Miscellaneous

Outstanding Shares
14,850,000
Free Float
13,649,000
Market Cap
$10.40 million
Optionable
No Data
Beta
0.88

Social Links

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:BFRI) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners